Skip to Main Content

Paper Details

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Cancer Discov
44
2021

Datasets

Release 1.2